New Data from U.S. Post-Approval Study Assess Ischemic Stroke and Intracranial Hemorrhage Rates in People with Non-Valvular Atrial Fibrillation Comparing Both Rivaroxaban with Warfarin and Apixaban wi
Go back to New Data from U.S. Post-Approval Study Assess Ischemic Stroke and Intracranial Hemorrhage Rates in People with Non-Valvular Atrial Fibrillation Comparing Both Rivaroxaban with Warfarin and Apixaban wi| Johnson & Johnson (NYSE: JNJ) | Delayed: 231.29 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $231.29 | 52 Week High | $126.07 | |||
| Open | $231.29 | 52 Week Low | $94.28 | |||
| Day High | $231.29 | P/E | 48.09 | |||
| Day Low | $231.29 | EPS | $4.81 | |||
| Volume | 111,021 | |||||
